Sangamo Therapeutics Inc
NASDAQ:SGMO
Sangamo Therapeutics Inc
Pre-Tax Income
Sangamo Therapeutics Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sangamo Therapeutics Inc
NASDAQ:SGMO
|
Pre-Tax Income
-$262.9m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-26%
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$1.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-16%
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
See Also
What is Sangamo Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-262.9m
USD
Based on the financial report for Dec 31, 2023, Sangamo Therapeutics Inc's Pre-Tax Income amounts to -262.9m USD.
What is Sangamo Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-26%
Over the last year, the Pre-Tax Income growth was -37%. The average annual Pre-Tax Income growth rates for Sangamo Therapeutics Inc have been -30% over the past three years , -31% over the past five years , and -26% over the past ten years .